{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T13:42:47Z","timestamp":1774532567118,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,2,24]],"date-time":"2018-02-24T00:00:00Z","timestamp":1519430400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Shanghai Committee of Science and Technology Fund","award":["15ZR1407600"],"award-info":[{"award-number":["15ZR1407600"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s12149-018-1245-0","type":"journal-article","created":{"date-parts":[[2018,2,24]],"date-time":"2018-02-24T10:57:51Z","timestamp":1519469871000},"page":"272-280","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The feasibility of 18F-FES and 18F-FDG microPET\/CT for early monitoring the effect of fulvestrant on sensitizing docetaxel by downregulating ER\u03b1 in ER\u03b1+ breast cancer"],"prefix":"10.1007","volume":"32","author":[{"given":"Shuai","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingxin","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiyu","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingjian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongyi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,24]]},"reference":[{"key":"1245_CR1","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ejca.2009.09.009","volume":"46","author":"RW Blamey","year":"2010","unstructured":"Blamey RW, Hornmark-Stenstam B, Ball G, Blichert-Toft M, Cataliotti L, Fourquet A, et al. ONCOPOOL\u2014a European database for 16,944 cases of breast cancer. Eur J Cancer (Oxf Engl 1990). 2010;46:56\u201371.","journal-title":"Eur J Cancer (Oxf Engl 1990)"},{"key":"1245_CR2","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/BF02967635","volume":"10","author":"J Kurebayashi","year":"2003","unstructured":"Kurebayashi J. Endocrine-resistant breast cancer: underlying mechanisms and strategies for overcoming resistance. Breast Cancer (Tokyo Jpn). 2003;10:112\u20139.","journal-title":"Breast Cancer (Tokyo Jpn)"},{"key":"1245_CR3","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1080\/07853890310014579","volume":"35","author":"L Murphy","year":"2003","unstructured":"Murphy L, Cherlet T, Lewis A, Banu Y, Watson P. New insights into estrogen receptor function in human breast cancer. Ann Med. 2003;35:614\u201331.","journal-title":"Ann Med"},{"key":"1245_CR4","doi-asserted-by":"publisher","first-page":"5337","DOI":"10.1158\/0008-5472.CAN-06-4582","volume":"67","author":"M Sui","year":"2007","unstructured":"Sui M, Huang Y, Park BH, Davidson NE, Fan W. Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death. Cancer Res. 2007;67:5337\u201344.","journal-title":"Cancer Res"},{"key":"1245_CR5","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s10549-009-0472-4","volume":"121","author":"M Sui","year":"2010","unstructured":"Sui M, Jiang D, Hinsch C, Fan W. Fulvestrant (ICI 182, 780) sensitizes breast cancer cells expressing estrogen receptor alpha to vinblastine and vinorelbine. Breast Cancer Res Treat. 2010;121:335\u201345.","journal-title":"Breast Cancer Res Treat"},{"key":"1245_CR6","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1200\/JCO.2003.02.063","volume":"21","author":"IC Henderson","year":"2003","unstructured":"Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21:976\u201383.","journal-title":"J Clin Oncol"},{"key":"1245_CR7","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S1470-2045(05)70094-2","volume":"6","author":"A Montero","year":"2005","unstructured":"Montero A, Fossella F, Hortobagyi G, Valero V. Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol. 2005;6:229\u201339.","journal-title":"Lancet Oncol"},{"key":"1245_CR8","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s10549-012-1994-8","volume":"134","author":"J Chang","year":"2012","unstructured":"Chang J, Sui M, Fan W. Estrogen receptor alpha attenuates therapeutic efficacy of paclitaxel on breast xenograft tumors. Breast Cancer Res Treat. 2012;134:969\u201380.","journal-title":"Breast Cancer Res Treat"},{"key":"1245_CR9","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1111\/j.1349-7006.2011.02050.x","volume":"102","author":"H Ikeda","year":"2011","unstructured":"Ikeda H, Taira N, Nogami T, Shien K, Okada M, Shien T, et al. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer. Cancer Sci. 2011;102:2038\u201342.","journal-title":"Cancer Sci"},{"key":"1245_CR10","first-page":"1526","volume":"32","author":"AH McGuire","year":"1991","unstructured":"McGuire AH, Dehdashti F, Siegel BA, Lyss AP, Brodack JW, Mathias CJ, et al. Positron tomographic assessment of 16 alpha-[18F] fluoro-17 beta-estradiol uptake in metastatic breast carcinoma. J Nucl Med. 1991;32:1526\u201331.","journal-title":"J Nucl Med"},{"key":"1245_CR11","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2967\/jnumed.107.047506","volume":"49","author":"LM Peterson","year":"2008","unstructured":"Peterson LM, Mankoff DA, Lawton T, Yagle K, Schubert EK, Stekhova S, et al. Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol. J Nucl Med. 2008;49:367\u201374.","journal-title":"J Nucl Med"},{"key":"1245_CR12","doi-asserted-by":"publisher","first-page":"e78192","DOI":"10.1371\/journal.pone.0078192","volume":"8","author":"Z Yang","year":"2013","unstructured":"Yang Z, Sun Y, Xue J, Yao Z, Xu J, Cheng J, et al. Can positron emission tomography\/computed tomography with the dual tracers fluorine-18 fluoroestradiol and fluorodeoxyglucose predict neoadjuvant chemotherapy response of breast cancer?\u2014a pilot study. PloS one. 2013;8:e78192.","journal-title":"PloS one"},{"key":"1245_CR13","doi-asserted-by":"publisher","first-page":"e0116341","DOI":"10.1371\/journal.pone.0116341","volume":"10","author":"Y Sun","year":"2015","unstructured":"Sun Y, Yang Z, Zhang Y, Xue J, Wang M, Shi W, et al. The preliminary study of 16alpha-[18F]fluoroestradiol PET\/CT in assisting the individualized treatment decisions of breast cancer patients. PloS one. 2015;10:e0116341.","journal-title":"PloS one"},{"key":"1245_CR14","first-page":"402","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. (San Diego, Calif) 2001;25:402\u20138.","journal-title":"MethodsCalif)"},{"key":"1245_CR15","first-page":"196","volume":"31","author":"YPZY Zhang","year":"2011","unstructured":"Zhang YPZY., Wang MW, et al. Fully automated synthesis of 16a [18F] fluoro-17b-estrogen using Explora GN\/LC dual module (in chinese). Zhonghua He Yi Xue Za Zhi. 2011;31:196\u2013200.","journal-title":"Zhonghua He Yi Xue Za Zhi"},{"key":"1245_CR16","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3892\/etm.2011.359","volume":"3","author":"T Osako","year":"2012","unstructured":"Osako T, Nishimura R, Okumura Y, Toyozumi Y, Arima N. Predictive significance of the proportion of ER-positive or PgR-positive tumor cells in response to neoadjuvant chemotherapy for operable HER2-negative breast cancer. Exp Ther Med. 2012;3:66\u201371.","journal-title":"Exp Ther Med"},{"key":"1245_CR17","doi-asserted-by":"publisher","first-page":"18060","DOI":"10.1073\/pnas.1018858109","volume":"109","author":"ST Bailey","year":"2012","unstructured":"Bailey ST, Shin H, Westerling T, Liu XS, Brown M. Estrogen receptor prevents p53-dependent apoptosis in breast cancer. Proc Natl Acad Sci USA. 2012;109:18060\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1245_CR18","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s10549-011-1488-0","volume":"131","author":"EH Lips","year":"2012","unstructured":"Lips EH, Mulder L, de Ronde JJ, Mandjes IA, Vincent A, Vrancken Peeters MT, et al. Neoadjuvant chemotherapy in ER+ HER2-breast cancer: response prediction based on immunohistochemical and molecular characteristics. Breast Cancer Res Treat. 2012;131:827\u201336.","journal-title":"Breast Cancer Res Treat"},{"key":"1245_CR19","doi-asserted-by":"publisher","first-page":"8195","DOI":"10.1158\/1078-0432.CCR-05-1258","volume":"11","author":"L Wu","year":"2005","unstructured":"Wu L, Tannock IF. Effect of the selective estrogen receptor modulator arzoxifene on repopulation of hormone-responsive breast cancer xenografts between courses of chemotherapy. Clin Cancer Res. 2005;11:8195\u2013200.","journal-title":"Clin Cancer Res"},{"key":"1245_CR20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/00001813-200401000-00009","volume":"15","author":"D Chen","year":"2004","unstructured":"Chen D, Hackl W, Ortmann O, Treeck O. Effects of a combination of exemestane and paclitaxel on human tumor cells in vitro. Anti Cancer Drugs. 2004;15:55\u201361.","journal-title":"Anti Cancer Drugs"},{"key":"1245_CR21","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1677\/erc.1.00905","volume":"12","author":"LA Martin","year":"2005","unstructured":"Martin LA, Pancholi S, Chan CM, Farmer I, Kimberley C, Dowsett M, et al. The anti-oestrogen ICI 182, 780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling. Endocr Relat Cancer. 2005;12:1017\u201336.","journal-title":"Endocr Relat Cancer"},{"key":"1245_CR22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0960-0760(01)00138-8","volume":"79","author":"JF Robertson","year":"2001","unstructured":"Robertson JF. Faslodex (ICI 182, 780), a novel estrogen receptor downregulator\u2014future possibilities in breast cancer. J Steroid Biochem Mol Biol. 2001;79:209\u201312.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"1245_CR23","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1158\/1078-0432.CCR-14-1178","volume":"21","author":"P Heidari","year":"2015","unstructured":"Heidari P, Deng F, Esfahani SA, Leece AK, Shoup TM, Vasdev N, et al. Pharmacodynamic imaging guides dosing of a selective estrogen receptor degrader. Clin Cancer Res. 2015;21:1340\u20137.","journal-title":"Clin Cancer Res"},{"key":"1245_CR24","doi-asserted-by":"publisher","first-page":"e0159916","DOI":"10.1371\/journal.pone.0159916","volume":"11","author":"S He","year":"2016","unstructured":"He S, Wang M, Yang Z, Zhang J, Zhang Y, Luo J, et al. Comparison of 18F-FES, 18F-FDG, and 18F-FMISO pet imaging probes for early prediction and monitoring of response to endocrine therapy in a mouse xenograft model of ER-positive breast cancer. PloS one. 2016;11:e0159916.","journal-title":"PloS one"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12149-018-1245-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-018-1245-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-018-1245-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,24]],"date-time":"2019-02-24T00:43:20Z","timestamp":1550969000000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12149-018-1245-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,24]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["1245"],"URL":"https:\/\/doi.org\/10.1007\/s12149-018-1245-0","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,24]]},"assertion":[{"value":"15 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}